Extended Treatment Duration of Artemether‐Lumefantrine in Ugandan Children with HIV on Efavirenz‐Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial
Authors:
- 24 January 2025
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (7) , 909-922
Abstract
Malaria and HIV co‐infection are prevalent in sub‐Saharan Africa causing significant drug interactions with co‐treatment. We previously reported a 30%‐70% reduction in exposure to the standard 3‐day (6‐dose) artemether‐lumefantrine (AL) treatment for malaria when given with efavirenz‐based HIV therapy, impacting malaria reinfection risk. We conducted a prospective, randomized study comparing the 3‐day regimen to an extended 5‐day (10‐dose) regimen with pharmacokinetic sampling for artemether, dihydroartemisinin, lumefantrine, and desbutyl‐lumefantrine (DBL) over 42 days. The primary outcome was comparative pharmacokinetics between regimens compared among children with HIV and among children without HIV receiving a 3‐day regimen as controls (median age 5.3 years [range 1.4‐13.9]; median weight 17.3 kg [range 8.7‐39.1]). Children with HIV (n = 57; median age 10.8 years [range 3.4‐17.1]; median weight 26.6 kg [range 14.6‐54.5]) contributed 76 malaria episodes, with 71 included in the analysis. Another 97 children without HIV (median age 5.3 years [range 1.4‐13.9]; median weight 17.3 kg [range 8.7‐39.1]) contributed 114 episodes of malaria, with 109 included in the analysis. In the setting of efavirenz, artemether, dihydroartemisinin, lumefantrine, and DBL cumulative exposure was 2.09, 2.31, 1.90, and 1.65 fold higher with 5‐day versus 3‐day AL (all P < .001), and comparable to 3‐day AL in children without HIV. The extended regimen in children with HIV did not result in a statistically significant reduction in recurrence risk at 28 or 42 days. Extending the duration of AL to 5 days compensated for a clinically significant reduction in all components of AL in the context of EFV‐based antiretroviral therapy in young children.Keywords
This publication has 27 references indexed in Scilit:
- Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in UgandaClinical Pharmacology & Therapeutics, 2022
- The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled TrialClinical Infectious Diseases, 2022
- High burden of malaria among Malawian adults on antiretroviral therapy after discontinuing prophylaxisAIDS, 2022
- Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan AfricaProceedings of the National Academy of Sciences, 2021
- Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated MalariaThe Journal of Infectious Diseases, 2016
- Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan ChildrenClinical Infectious Diseases, 2016
- Antiretroviral Agents and Prevention of Malaria in HIV-Infected Ugandan ChildrenNew England Journal of Medicine, 2012
- A Perspective on Efflux Transport Proteins in the LiverClinical Pharmacology & Therapeutics, 2012
- Simplified antimalarial therapeutic monitoring: using the day-7 drug level?Trends in Parasitology, 2008
- Antimalarial dosing regimens and drug resistanceTrends in Parasitology, 2008